Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5).
第一作者:
E,Schuler
第一单位:
Department for Hematology, Oncology and Clinical Immunology, University Hospital, Heinrich-Heine-University, Duesseldorf, Germany.
作者:
医学主题词
成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);染色体缺失(Chromosome Deletion);染色体, 人, 5对(Chromosomes, Human, Pair 5);女(雌)性(Female);人类(Humans);免疫因子类(Immunologic Factors);Kaplan-Meiers评估(Kaplan-Meier Estimate);男(雄)性(Male);中年人(Middle Aged);骨髓增生异常综合征(Myelodysplastic Syndromes);比例危险度模型(Proportional Hazards Models);前瞻性研究(Prospective Studies);沙立度胺(Thalidomide);治疗结果(Treatment Outcome)
DOI
10.1038/leu.2015.340
PMID
26668126
发布时间
2018-12-02
- 浏览5
Leukemia
1580-2页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



